Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

2.

McMahon

TJ

,

Darrow

CC

,

Hoehn

BA

,

Zhu

H

.

Generation and export of red blood cell ATP in health and disease

.

Front Physiol

.

2021

;

12

:

754638

.

3.

Brown

KA

.

Erythrocytes metabolism and enzyme defects

.

Lab Med

.

1996

;

27

(

5

):

329

-

333

.

4.

Poillon

WN

,

Kim

BC

.

2,3-diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S

.

Blood

.

1990

;

76

(

5

):

1028

-

1036

.

5.

Poillon

WN

,

Kim

BC

,

Labotka

RJ

,

Hicks

CU

,

Kark

JA

.

Antisickling effects of 2,3-diphosphoglycerate depletion

.

Blood

.

1995

;

85

(

11

):

3289

-

3296

.

6.

Eaton

WA

,

Bunn

HF

.

Treating sickle cell disease by targeting HbS polymerization

.

Blood

.

2017

;

129

(

20

):

2719

-

2726

.

7.

Grace

RF

,

Bianchi

P

,

van Beers

EJ

, et al.

Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study

.

Blood

.

2018

;

131

(

20

):

2183

-

2192

.

8.

Zanella

A

,

Fermo

E

,

Bianchi

P

,

Valentini

G

.

Red cell pyruvate kinase deficiency: molecular and clinical aspects

.

Br J Haematol

.

2005

;

130

(

1

):

11

-

25

.

9.

Vander Heiden

MG

.

Targeting cancer metabolism: a therapeutic window opens

.

Nat Rev Drug Discov

.

2011

;

10

(

9

):

671

-

684

.

10.

Zahra

K

,

Dey

T

,

Ashish

,

Mishra

SP

,

Pandey

U

.

Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis

.

Front Oncol

.

2020

;

10

:

159

.

11.

Kung

C

,

Hixon

J

,

Kosinski

PA

, et al.

AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency

.

Blood

.

2017

;

130

(

11

):

1347

-

1356

.

12.

Al-Samkari

H

,

Galacteros

F

,

Glenthoj

A

, et al.

Mitapivat versus placebo for pyruvate kinase deficiency

.

N Engl J Med

.

2022

;

386

(

15

):

1432

-

1442

.

13.

Glenthoj

A

,

van Beers

EJ

,

Al-Samkari

H

, et al.

Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial

.

Lancet Haematol

.

2022

;

9

(

10

):

e724

-

e732

.

14.

Yang

H

,

Merica

E

,

Chen

Y

, et al.

Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers

.

Clin Pharmacol Drug Dev

.

2019

;

8

(

2

):

246

-

259

.

15.

Matte

A

,

Federti

E

,

Kung

C

, et al.

The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a beta-thalassemia mouse model

.

J Clin Invest

.

2021

;

131

(

10

):

e144206

.

16.

Kuo

KHM

,

Layton

DM

,

Lal

A

, et al.

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent alpha-thalassaemia or beta-thalassaemia: an open-label, multicentre, phase 2 study

.

Lancet

.

2022

;

400

(

10351

):

493

-

501

.

17.

Gladwin

MT KG

,

Novelli

EM

. Sickle Cell Disease.

McGraw Hill/Medical

;

2021

.

18.

Charache

S

,

Grisolia

S

,

Fiedler

AJ

,

Hellegers

AE

.

Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia

.

J Clin Invest

.

1970

;

49

(

4

):

806

-

812

.

19.

Cohen-Solal

M

,

Prehu

C

,

Wajcman

H

, et al.

A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry)

.

Br J Haematol

.

1998

;

103

(

4

):

950

-

956

.

20.

Alli

N

,

Coetzee

M

,

Louw

V

, et al.

Sickle cell disease in a carrier with pyruvate kinase deficiency

.

Hematology

.

2008

;

13

(

6

):

369

-

372

.

21.

Xu

JZ

,

Thein

SL

.

The carrier state for sickle cell disease is not completely harmless

.

Haematologica

.

2019

;

104

(

6

):

1106

-

1111

.

22.

Wang

X

,

Gardner

K

,

Tegegn

MB

, et al.

Genetic variants of PKLR are associated with acute pain in sickle cell disease

.

Blood Adv

.

2022

;

6

(

11

):

3535

-

3540

.

23.

Wang

X

,

Fu

YP

,

Li

Q

, et al.

Pklr variants associated with acute pain in sickle cell disease influence ATP concentrations in red blood cells

.

Blood

.

2022

;

140

:

954

-

956

.

24.

Rab

MAE

,

Bos

J

,

van Oirschot

BA

, et al.

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

.

Blood

.

2021

;

137

(

21

):

2997

-

3001

.

25.

Shrestha

A

,

Chi

M

,

Wagner

K

, et al.

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice

.

Blood Adv

.

2021

;

5

(

9

):

2385

-

2390

.

26.

Quezado

ZMN

,

Kamimura

S

,

Smith

M

, et al.

Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model

.

Blood Cells Mol Dis

.

2022

;

95

:

102660

.

27.

Xu

JZ

,

Conrey

A

,

Frey

I

, et al.

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

.

Blood

.

2022

;

140

(

19

):

2053

-

2062

.

28.

van Dijk

MJ

,

Rab

MAE

,

van Oirschot

BA

, et al.

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study

.

Am J Hematol

.

2022

;

97

(

7

):

E226

-

E229

.

29.

Brown

RC

,

K; Kalfa

TA

,

Kuypers

FA

, et al.

FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after a single dose and after multiple daily doses in a phase 1 study of patients with sickle cell disease

.

Blood

.

2020

;

136

:

19

-

20

.

30.

Schroeder

P

,

Fulzele

K

,

Forsyth

S

, et al.

Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease

.

J Pharmacol Exp Ther

.

2022

;

380

(

3

):

210

-

219

.

31.

Forsyth

S

,

Schroeder

P

,

Geib

J

, et al.

Safety, pharmacokinetics, and pharmacodynamics of etavopivat (FT-4202), an allosteric activator of pyruvate kinase-R, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-human phase 1 trial

.

Clin Pharmacol Drug Dev

.

2022

;

11

(

5

):

654

-

665

.

32.

Bunn

HF

.

Oxygen delivery in the treatment of anemia

.

N Engl J Med

.

2022

;

387

(

25

):

2362

-

2365

.

33.

Sunshine

HR

,

Hofrichter

J

,

Ferrone

FA

,

Eaton

WA

.

Oxygen binding by sickle cell hemoglobin polymers

.

J Mol Biol

.

1982

;

158

(

2

):

251

-

273

.

34.

Henry

ER

,

Harper

J

,

Glass

KE

,

Metaferia

B

,

Louis

JM

,

Eaton

WA

.

MWC allosteric model explains unusual hemoglobin-oxygen binding curves from sickle cell drug binding

.

Biophys J

.

2021

;

120

(

12

):

2543

-

2551

.

35.

Henry

ER

,

Metaferia

B

,

Li

Q

, et al.

Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin

.

Blood

.

2021

;

138

(

13

):

1172

-

1181

.

36.

Howard

J

,

Ataga

KI

,

Brown

RC

, et al.

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial

.

Lancet Haematol

.

2021

;

8

(

5

):

e323

-

e333

.

37.

Inusa

BPD

,

Casale

M

,

Campbell

A

,

Archer

N

.

Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?

.

Lancet Haematol

.

2021

;

8

(

5

):

e306

-

e307

.

38.

Konté

K

,

Baas

KPA

,

Afzali-Hashemi

L

, et al.

Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism in adult patients with sickle cell disease; preliminary results of the Coverage Study

.

Blood

.

2022

;

140

:

2535

-

2536

.

39.

Duhm

J

.

Effects of 2,3-diphosphoglycerate and other organic phosphate compounds on oxygen affinity and intracellular pH of human erythrocytes

.

Pflügers Arch

.

1971

;

326

(

4

):

341

-

356

.

40.

Hofrichter

J

,

Ross

PD

,

Eaton

WA

.

Supersaturation in sickle cell hemoglobin solutions

.

Proc Natl Acad Sci U S A

.

1976

;

73

(

9

):

3035

-

3039

.

41.

Goldberg

MA

,

Husson

MA

,

Bunn

HF

.

Participation of hemoglobins A and F in polymerization of sickle hemoglobin

.

J Biol Chem

.

1977

;

252

(

10

):

3414

-

3421

.

42.

Briehl

RW

.

Gelation of sickle cell hemoglobin. IV. Phase transitions in hemoglobin S gels: separate measures of aggregation and solution--gel equilibrium

.

J Mol Biol

.

1978

;

123

(

4

):

521

-

538

.

43.

Henry

ER

,

Mozzarelli

A

,

Viappiani

C

, et al.

Experiments on hemoglobin in single crystals and silica gels distinguish among allosteric models

.

Biophys J

.

2015

;

109

(

6

):

1264

-

1272

.

44.

Bunn

HF

.

Pathogenesis and treatment of sickle cell disease

.

N Engl J Med

.

1997

;

337

(

11

):

762

-

769

.

45.

Eaton

WA

,

Hofrichter

J

.

Hemoglobin S gelation and sickle cell disease

.

Blood

.

1987

;

70

(

5

):

1245

-

1266

.

46.

Li

Q

,

Henry

ER

,

Hofrichter

J

, et al.

Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease

.

Proc Natl Acad Sci U S A

.

2017

;

114

(

5

):

E689

-

E696

.

47.

Park

Y

,

Best

CA

,

Auth

T

, et al.

Metabolic remodeling of the human red blood cell membrane

.

Proc Natl Acad Sci U S A

.

2010

;

107

(

4

):

1289

-

1294

.

48.

Jensen

M

,

Shohet

SB

,

Nathan

DG

.

The role of red cell energy metabolism in the generation of irreversibly sickled cells in vitro

.

Blood

.

1973

;

42

(

6

):

835

-

842

.

49.

El Nemer

W

,

Godard

A

,

El Hoss

S

.

Ineffective erythropoiesis in sickle cell disease: new insights and future implications

.

Curr Opin Hematol

.

2021

;

28

(

3

):

171

-

176

.

50.

Bennett

V

,

Stenbuck

PJ

.

The membrane attachment protein for spectrin is associated with band 3 in human erythrocyte membranes

.

Nature

.

1979

;

280

(

5722

):

468

-

473

.

51.

Ferru

E

,

Giger

K

,

Pantaleo

A

, et al.

Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3

.

Blood

.

2011

;

117

(

22

):

5998

-

6006

.

52.

Mohandas

N

,

Gallagher

PG

.

Red cell membrane: past, present, and future

.

Blood

.

2008

;

112

(

10

):

3939

-

3948

.

53.

Lux

SEt

.

Anatomy of the red cell membrane skeleton: unanswered questions

.

Blood

.

2016

;

127

(

2

):

187

-

199

.

54.

Noomuna

P

,

Risinger

M

,

Zhou

S

, et al.

Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease

.

Br J Haematol

.

2020

;

190

(

4

):

599

-

609

.

55.

Terra

HT

,

Saad

MJ

,

Carvalho

CR

,

Vicentin

DL

,

Costa

FF

,

Saad

ST

.

Increased tyrosine phosphorylation of band 3 in hemoglobinopathies

.

Am J Hematol

.

1998

;

58

(

3

):

224

-

230

.

56.

Le

K

,

Wang

X

,

Lundt

M

, et al.

Activating pyruvate kinase improves red blood cell integrity by reducing Band3 tyrosine phosphorylation

.

Blood

.

2022

;

140

:

5395

-

5396

.

57.

Lundt

M

,

Asomaning

N

,

Frey

I

, et al.

The pyruvate kinase activator mitapivat improves red blood cell deformability and sickling kinetics in adult patients with sickle cell disease

.

Blood

.

2022

;

140

:

2508

-

2509

.

58.

Little

JA

.

RBC, heal thyself: PK activators in SCD

.

Blood

.

2022

;

140

(

19

):

2005

-

2006

.

59.

Grace

RF

,

Rose

C

,

Layton

DM

, et al.

Safety and efficacy of mitapivat in pyruvate kinase deficiency

.

N Engl J Med

.

2019

;

381

(

10

):

933

-

944

.

60.

Collaborators GBDSCD

.

Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021

.

Lancet Haematol

.

2023

;

10

(

8

):

e585

-

e599

.

61.

Migotsky

M

,

Beestrum

M

,

Badawy

SM

.

Recent advances in sickle-cell disease therapies: a review of voxelotor, crizanlizumab, and L-glutamine

.

Pharmacy (Basel)

.

2022

;

10

(

5

):

10050123

.

62.

Salinas Cisneros

G

,

Thein

SL

.

Recent advances in the treatment of sickle cell disease

.

Front Physiol

.

2020

;

11

:

435

.

63.

Telen

MJ

.

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease

.

Blood

.

2016

;

127

(

7

):

810

-

819

.

64.

Thornburg

CD

,

Calatroni

A

,

Telen

M

,

Kemper

AR

.

Adherence to hydroxyurea therapy in children with sickle cell anemia

.

J Pediatr

.

2010

;

156

(

3

):

415

-

419

.

65.

Cronin

RM

,

Lin

CJ

,

Chiang

C

,

MacEwan

SR

,

DeBaun

MR

,

Hyer

JM

.

The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease

.

Blood Adv

.

2023

;

7

(

13

):

3114

-

3116

.

66.

Tisdale

JF

,

Thein

SL

,

Eaton

WA

.

Treating sickle cell anemia

.

Science

.

2020

;

367

(

6483

):

1198

-

1199

.

67.

Menzel

S

,

Garner

C

,

Gut

I

, et al.

A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15

.

Nat Genet

.

2007

;

39

(

10

):

1197

-

1199

.

68.

Tanhehco

YC

,

Nathu

G

,

Vasovic

LV

.

Development of curative therapies for sickle cell disease

.

Front Med (Lausanne)

.

2022

;

9

:

1055540

.

69.

Metaferia

B

,

Cellmer

T

,

Dunkelberger

EB

, et al.

Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease

.

Proc Natl Acad Sci U S A

.

2022

;

119

(

40

):

e2210779119

.